Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia

Reuters

Sep 25

<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia

Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate $(ADC)$, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2570932610"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570932610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570932610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 18:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570932610","market":"nz","top_or_hot":-1,"title":"Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-25 18:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL9dMQFw:1","article_id":"2570932610","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570932610","pubTimestamp":1758795278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia. Sino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate , in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"中国生物制药有限公司宣布首例患者入组创新CDH17 ADC LM-350澳大利亚I期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia\n    \n\nSino Biopharmaceutical Limited has announced the completion of enrollment of the first patient in a Phase I clinical trial for LM-350, a CDH17 antibody-drug conjugate $(ADC)$, in Australia. LM-350 is an innovative therapy developed by LaNova Medicines Limited, a wholly-owned subsidiary of the company. The clinical study is an open-label, dose escalation and dose expansion Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of LM-350 in patients with advanced solid tumors. No clinical results have been presented at this time. The company indicated that the trial marks the official entry of LM-350 into the clinical development stage, with plans to advance the project further.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}